Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Salix Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01647906
First received: June 27, 2012
Last updated: September 19, 2014
Last verified: September 2014

June 27, 2012
September 19, 2014
May 2012
December 2017   (final data collection date for primary outcome measure)
  • Freedom from fecal incontinence reintervention [ Time Frame: Through 36 months after the last Solesta treatment ] [ Designated as safety issue: No ]
    The primary effectiveness endpoint is freedom from Fecal Incontinence Reintervention. Patients will be evaluated at 3, 6, 12, 24, and 36 months after the last Solesta treatment for the occurrence (or lack of occurrence) of Fecal Incontinence Reintervention. Fecal Incontinence Reintervention includes Fecal Incontinence treatment of sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, sacral nerve stimulation (SNS) or other surgical interventions that occur more than 3 months after the last primary Solesta treatment.
  • Occurrence of device related adverse events (AEs) [ Time Frame: Through 36 months after the last Solesta treatment ] [ Designated as safety issue: Yes ]
    The primary safety endpoint will be the occurrence of device related AEs. Patients will be evaluated at 3, 6, 12, 24, and 36 months after the last Solesta treatment. All AEs will be collected and causal relationship to the device will be assessed by the investigator.
  • Freedom from fecal incontinence reintervention [ Time Frame: Through 36 months after the last Solesta treatment ] [ Designated as safety issue: No ]
    The primary effectiveness endpoint is freedom from Fecal Incontinence Reintervention. Patients will be evaluated at 6, 12, 24, and 36 months after the last Solesta treatment for the occurrence (or lack of occurrence) of Fecal Incontinence Reintervention. Fecal Incontinence Reintervention includes fecal incontincence treatment of sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, sacral nerve stimulation (SNS) or other surgical interventions that occur more than 4 months after the last primary Solesta treatment.
  • Occurrence of device related AEs [ Time Frame: Through 36 months after the last Solesta treatment ] [ Designated as safety issue: Yes ]
    The primary safety endpoint will be the occurrence of device related AEs. Patients will be evaluated at 3, 6, 12, 24, and 36 months after the last Solesta treatment. All AEs will be collected and causal relationship to the device will be assessed by the investigator.
Complete list of historical versions of study NCT01647906 on ClinicalTrials.gov Archive Site
  • Fecal Incontinence Quality of Life (FIQL) [ Time Frame: Assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment. ] [ Designated as safety issue: No ]
    The effectiveness endpoint of Fecal Incontinence Quality of Life using the Rockwood instrument will be assessed at baseline, 3, 6, 12, and 36 months after last Solesta treatment. Patients will fill out a questionnaire at screening visit and at follow up visits. The Fecal Incontinence Quality of Life instrument is a questionnaire completed by patients that assesses the impact of quality of life as it relates to Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The FIQL instrument consists of a total of 29 questions.
  • Cleveland Clinic Florida Fecal Incontinence Score (CCFIS) [ Time Frame: Assessed at baseline,3, 6, 12, and 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    The effectiveness endpoint of CCFIS will be assessed at baseline, 6, 12, and 36 months after last Solesta treatment. The investigator will calculate the CCFIS based on a patient interview. The CCFIS is a summed score of 5 individual parameters (i.e., frequency of incontinence to gas, liquid, solid, of need to wear pad, and of lifestyle changes).
  • Global Perceived Effect Score [ Time Frame: Assessed at 6, 12 and 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    The effectiveness endpoint of Global Perceived Effect Score will be assessed at 6, 12 and 36 months after last Solesta treatment. Global perceived effect is a subjective score and reflects the patient perception of their degree of FI after treatment compared to the period before treatment and ranges from 1-7 points.
  • Time to Fecal Incontinence Reintervention [ Time Frame: Assessed from 6 to 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    For patients who undergo Fecal Incontinence Reintervention the effectiveness endpoint of Time to Fecal Incontinence Reintervention will be measured from the date of last treatment with Solesta to the date of first Fecal Incontinence Reintervention. Fecal incontinence reinterventions will include any of the following FI treatments: sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, SNS or other surgical interventions.
  • Anatomic stability of the Solesta [ Time Frame: Assessed at time of Solesta treatment and again at 6 and 36 months after the last Solesta treatment. ] [ Designated as safety issue: No ]
    Assess the relative anatomic stability of the Solesta Injectable Bulking Agent in a subpopulation of patients enrolled at 3-4 sites as assessed by transrectal ultrasound. Solesta will be assessed by comparing anatomical positioning of the Solesta implant, as determined by transrectal ultrasound at Visit 3a (for patients who did not receive a second Solesta treatment) or Visit 3b (for patients who received a second Solesta treatment at Visit 3a) to positioning at 6 and 36 months after the last Solesta treatment.
  • Occurrence of any peri-injection device related infectious adverse events. [ Time Frame: Assessed from time of injection up to 2 weeks after Solesta treatment ] [ Designated as safety issue: Yes ]
    A secondary safety endpoint will be the occurrence of peri-injection device related infectious Adverse Events for patients treated with or without prophylactic antibiotics (as decided by treating physician) prior to injection.
  • Fecal Incontinence Quality of Life [ Time Frame: Assessed at baseline, 6, 12, and 36 months after last Solesta treatment. ] [ Designated as safety issue: No ]
    The effectiveness endpoint of Fecal Incontinence Quality of Life using the Rockwood instrument will be assessed at baseline, 6, 12, and 36 months after last Solesta treatment. Patients will fill out a questionnaire at screening visit and at follow up visits. The Fecal Incontinence Quality of Life instrument is a questinaire completd by patients that assesses the impact of quality of life as it relates to Lifestyle, Coping/Behavior, Depression/Self perception and Embarrassment. The FIQL instrument consists of a total of 29 questions.
  • Cleveland Clinic Florida Fecal Incontinence Score [ Time Frame: Assessed at baseline, 6, 12, and 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    The effectiveness endpoint of Cleveland Clinic Florida Fecal Incontinence Score will be assessed at baseline, 6, 12, and 36 months after last Solesta treatment. The investigator will calculate the CCFIS based on a patient interview. The CCFIS is a summed score of 5 individual parameters (i.e., frequency of incontinence to gas, liquid, solid, of need to wear pad, and of lifestyle changes).
  • Global Perceived Effect Score [ Time Frame: Assessed at 6, 12 and 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    The effectiveness endpoint of Global Perceived Effect Score will be assessed at 6, 12 and 36 months after last Solesta treatment. Global perceived effect is a subjective score and reflects the patient perception of their degree of FI after treatment compared to the period before treatment and ranges from 1-7 points.
  • Time to Fecal Incontincence Reintervention [ Time Frame: Assessed from 6 to 36 months after last Solesta treatment ] [ Designated as safety issue: No ]
    For patients who undergo Fecal Incontincence Reintervention the effectiveness endpoint of Time to Fecal Incontincence Reintervention will be measured from the date of last treatment with Solesta to the date of first Fecal Incontincence Reintervention. Fecal incontinence reinterventions will include any of the following FI treatments: sphincteroplasty, implantation of artificial bowel sphincter, retreatment with Solesta, graciloplasty, SNS or other surgical interventions.
  • Anatomic stability of the Solesta [ Time Frame: Assessed at time of Solesta treatment and agina at 6 and 36 months after the last Solesta treatment. ] [ Designated as safety issue: No ]
    Asess the relative anatomic stability of the Solesta Injectable Bulking Agent in a subpopulation of patients enrolled at 3-4 sites as assessed by ultrasound. Relative anatomic stability of Solesta will be assessed by comparing anatomical positioning of the Solesta implant, as determined by ultrasound, at the time of injection to positioning at 6 and 36 months after the last Solesta treatment to 1) confirm the presence or absence of Solesta implants and 2) determine if any local shift has occurred.
  • Occurence of any peri-injection device related infectious adverse events. [ Time Frame: Assessed from time of injection upto 2 weeks after Solesta treament ] [ Designated as safety issue: Yes ]
    A secondary safety endpoint will be the occurrence of peri-injection device related infectious Adverse Events for patients treated with or without prophylactic antibiotics (as decided by treating physician) prior to injection.
Not Provided
Not Provided
 
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)

The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with Fecal Incontinence.

Fecal Incontinence
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
244
December 2017
December 2017   (final data collection date for primary outcome measure)

Inclusion Criteria: A patient will be eligible for study participation if he/she meets the following criteria:

  • Able to fluently speak and understand the language in which the study is being conducted and able to provide meaningful written informed consent for the study.
  • Have FI, have failed conservative therapy (e.g., diet, fiber therapy, medications that treat diarrhea), and are scheduled to receive Solesta treatment.
  • Females must be of non-childbearing potential; or females of childbearing (reproductive) potential must agree to use an acceptable method of contraception for at least the first 6 months of study participation and have a negative urine pregnancy test at Visit 1 (Screening/Baseline) and immediately prior to receiving initial Solesta treatment. Women who are surgically sterile or those who are post menopausal for at least 2 years prior to entering the study are not considered to be of childbearing potential.
  • Willing to return to the study facility for the post treatment evaluation.

Exclusion Criteria: A patient will be excluded from the study if he/she meets any of the following criteria:

  • Is currently pregnant, breastfeeding, or is planning to become pregnant over the course of the study.
  • Has an active inflammatory bowel disease.
  • Has an immunodeficiency disorder or ongoing immunosuppressive therapy.
  • Has received previous radiation treatment to the pelvic area.
  • Has significant mucosal or full thickness rectal prolapse.
  • Has active anorectal conditions including: abscess, fissures, sepsis, bleeding, proctitis, or other infections.
  • Has anorectal atresia, tumors, stenosis or malformation.
  • Has a rectocele.
  • Has rectal varices.
  • Has presence of existing implant including Solesta, artificial bowel sphincter, or sacral nerve stimulator (activated or inactivated).
  • Has an allergy to hyaluronic acid (HA) based products.
  • Has an anastomosis to the rectum or anus within 10 cm of the dentate line.
  • Has an unstable condition (e.g., psychiatric disorder, a recent history of substance abuse) or otherwise thought to be unreliable or incapable of complying with the requirements of the post-approval study protocol.
  • Has any disorder that, in the opinion of the Investigator, might interfere with the conduct of the study.
  • Has undergone sphincteroplasty, graciloplasty, or other surgical interventions (without the use of an implanted device) for treatment of fecal incontinence within 12 months of enrollment.
  • Has any bleeding disorder.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01647906
CL SLP001
No
Salix Pharmaceuticals
Salix Pharmaceuticals
Not Provided
Not Provided
Salix Pharmaceuticals
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP